Sinphar Pharmaceutical Co Ltd (1734) - Total Liabilities
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) has total liabilities worth NT$2.61 Billion TWD (≈ $82.31 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Sinphar Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Sinphar Pharmaceutical Co Ltd - Total Liabilities Trend (2002–2025)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Sinphar Pharmaceutical Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Sinphar Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sinphar Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taigen Biopharmaceuticals Holdings Ltd
TWO:4157
|
Taiwan | NT$92.38 Million |
|
Smart Sand Inc
NASDAQ:SND
|
USA | $101.55 Million |
|
Asia Electronic Material Co Ltd
TWO:4939
|
Taiwan | NT$1.31 Billion |
|
Xplora Technologies As
OL:XPLRA
|
Norway | Nkr1.64 Billion |
|
Platinum Group Metals Ltd
TO:PTM
|
Canada | CA$4.81 Million |
|
Hup Seng Industries Bhd
KLSE:5024
|
Malaysia | RM86.97 Million |
|
ÜSTRA Hannoversche Verkehrsbetriebe Aktiengesellschaft
F:HVB
|
Germany | €279.51 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Sinphar Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 1734 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinphar Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinphar Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual total liabilities of Sinphar Pharmaceutical Co Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$2.44 Billion ≈ $76.81 Million |
-11.42% |
| 2024-12-31 | NT$2.75 Billion ≈ $86.71 Million |
-3.54% |
| 2023-12-31 | NT$2.85 Billion ≈ $89.89 Million |
-3.88% |
| 2022-12-31 | NT$2.97 Billion ≈ $93.52 Million |
-5.58% |
| 2021-12-31 | NT$3.14 Billion ≈ $99.05 Million |
+5.39% |
| 2020-12-31 | NT$2.98 Billion ≈ $93.98 Million |
+9.93% |
| 2019-12-31 | NT$2.71 Billion ≈ $85.50 Million |
+10.52% |
| 2018-12-31 | NT$2.46 Billion ≈ $77.36 Million |
+1.61% |
| 2017-12-31 | NT$2.42 Billion ≈ $76.13 Million |
-0.33% |
| 2016-12-31 | NT$2.42 Billion ≈ $76.38 Million |
-0.08% |
| 2015-12-31 | NT$2.43 Billion ≈ $76.44 Million |
+1.71% |
| 2014-12-31 | NT$2.39 Billion ≈ $75.15 Million |
+7.96% |
| 2013-12-31 | NT$2.21 Billion ≈ $69.61 Million |
+19.74% |
| 2012-12-31 | NT$1.85 Billion ≈ $58.13 Million |
-6.71% |
| 2011-12-31 | NT$1.98 Billion ≈ $62.32 Million |
+27.41% |
| 2010-12-31 | NT$1.55 Billion ≈ $48.91 Million |
+4.13% |
| 2009-12-31 | NT$1.49 Billion ≈ $46.97 Million |
-18.01% |
| 2008-12-31 | NT$1.82 Billion ≈ $57.29 Million |
+24.14% |
| 2007-12-31 | NT$1.46 Billion ≈ $46.15 Million |
+31.83% |
| 2006-12-31 | NT$1.11 Billion ≈ $35.00 Million |
-7.00% |
| 2005-12-31 | NT$1.19 Billion ≈ $37.64 Million |
+15.96% |
| 2004-12-31 | NT$1.03 Billion ≈ $32.46 Million |
-7.83% |
| 2003-12-31 | NT$1.12 Billion ≈ $35.22 Million |
+43.92% |
| 2002-12-31 | NT$776.65 Million ≈ $24.47 Million |
-- |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more